PG
MRTX

PEAK6 Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

PEAK6 Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,100
Closed -$98K – 5183
2015
Q4 		$98K Sell
3,100
-400
-11% -$14.1K ﹤0.01% 3968
2015
Q3 		$120K Buy
+3,500
New +$106K ﹤0.01% 4179

Other funds holding MRTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PEAK6 Group's MRTX Position: Q1 2016 in Review

PEAK6 Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2016, closing a stake of 3,100 shares — an estimated $98K sold.

PEAK6 Group first reported a position in MRTX in Q3 2015 and held it in 2 quarters. The position peaked at $120K in Q3 2015. 68 funds tracked by Wall St. Rank hold MRTX as of Q1 2016.

  • PEAK6 Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • PEAK6 Group sold 3,100 Mirati Therapeutics, Inc. Common Stock shares in Q1 2016, an estimated $98K.
  • PEAK6 Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 2 quarters.
  • PEAK6 Group's Mirati Therapeutics, Inc. Common Stock position peaked at $120K in Q3 2015.
  • 68 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2016.

Based on PEAK6 Group's 13F filing for Q1 2016, filed 13 May 2016.